As a headline, this seems like a harsh statement to make. As an observation of the organisation and effectiveness of England’s healthcare model, perhaps less […]
Whilst watching EASD2020 this week, during the session on developing better insulins, a question was asked by multiple participants in relation to faster insulins. This […]
Warning: What is discussed in this post is not recommended by the manufacturers and not aligned with the European Medicines Agency sign off for Lyumjev […]
In the second article in this series looking at ultra-rapid insulin, we talk about Lilly’s new kid on the block: Ultra-Rapid Lispro (URLi) Ultra-Rapid Lispro […]
Around the time of launching Fiasp, Novo Nordisk embarked on a wider study of its use in Continuous Subcutaneous Insulin Infusion (CSII), or pumping as […]
After six months of leaving Fiasp on the shelf, and occasionally using it as an adjunct injection when fast carbs were consumed (where it still […]
Harking back to a disco classic, I have to put my hands up and admit that I’ve reached the end of my tether with Fiasp […]
Warning: What is discussed in this post is not recommended by the manufacturer and not aligned with the European Medicines Agency sign off for Fiasp. […]
One of the things that I’ve previously noted is that I’ve seen a fair amount of variability in using Fiasp, both in insulin sensitivity and […]
I’ve written about the various curveballs that Fiasp has thrown at me on multiple occasions, and for the past few weeks I’ve continued to observe […]
Copyright © 2024 | WordPress Theme by MH Themes